Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in
2035
• Claims cover methods of treating cancer with all commercial dosage strengths of Rubraca®
• This will be the 11th Orange Book-listed patent for Rubraca
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the United States Patent and Trademark Office issued United States
Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations.
The patent claims cover methods of treating cancer with commercial Rubraca product, including all commercial dosage strengths (200,
250 and 300mg). The high dosage strength rucaparib formulation patent expires in 2035, and will join multiple patents directed to
rucaparib, rucaparib camsylate, and methods of treatment as the 11th Orange Book-listed patent for rucaparib.
“We have multiple families of patents protecting Rubraca in the U.S., including composition of matter, salts/polymorphs, dosage
forms and formulations, and methods of use, and we continue to add new patents, including this high dosage strength method of
treatment patent,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “Each additional patent provides further
protection for Rubraca, and this is relevant not only to our current indications in ovarian cancer, but also to multiple potential
additional indications based on our ongoing and substantial clinical development programs.”
About Rubraca® (rucaparib)
Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including
ovarian, metastatic castration-resistant prostate, and bladder cancers, as monotherapy, and in combination with other anti-cancer
agents. Exploratory studies in other tumor types are also underway. Clovis holds worldwide rights for Rubraca. Rubraca is an
unlicensed medical product outside of the U.S. and Europe.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer
agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets
of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to
the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has
additional offices in San Francisco and Oakland, California and Cambridge, UK. Please visit
clovisoncology.com for more information.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis
Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of
forward-looking statements contained in this press release include, among others, statements regarding our expectation of the
expiration of and the coverage provided by certain patents in our portfolio. Such forward-looking statements involve substantial
risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that
expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties
inherent in the actions by the United States Patent and Trademark Office and third-party challenges to the validity, enforceability
or scope of our patents. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further
description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.
Clovis Oncology
Breanna Burkart
303.625.5023
bburkart@clovisoncology.com
or
Anna Sussman
303.625.5022
asussman@clovisoncology.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005365/en/